When: $395-$405 capitulation with RSI at 35-45 and stabilization

Then: Higher-conviction reload opportunity

HOLD - Do not add to position, reject tiered entry plans, maintain existing allocation only

• RSI at 62.51 showing bearish divergence as momentum declines from August highs while price reaches 52-week highs
• MACD histogram at negative 1.55 is first momentum divergence against 36.8% four-month rally; not 'normal cooling'
• Forward P/E of 17.9x relies on $24.41 EPS consensus that could compress to 15x in higher-for-longer environment, implying fair value closer to $365 not $488
• Bull case of 20-22x forward earnings requires both earnings beat AND multiple expansion in 93% no-cut regime
• AMGN carries $43.3 billion net debt against $8.65 billion trailing free cash flow; net debt to EBITDA ~2.5x manageable only in benign rate environment
• Tavneos UK withdrawal data is asymmetric risk - if localized, doesn't help bull case; if spreads, could meaningfully impact revenue
• Barron's noted AMGN shares declined on positive Repatha data - when good news doesn't move the stock, news is priced in
• Healthcare's 23.2% six-month outperformance vs S&P by 11.5 percentage points signals crowded trade vulnerable to mean reversion
• Stops fail in biotech on overnight FDA announcements, competitor trial results, or sector contagion - $395 stop becomes meaningless on 5-8% overnight gap
• Dividend at 2.27% does not compensate for 20-30% equity drawdown risk

→ vs aggressive: RSI at 62.51 is not 'below 70 absolution' - the declining momentum from August highs is textbook bearish divergence that resolves fast, especially in names up 36.8%

→ vs aggressive: Negative MACD histogram at negative 1.55 is first momentum divergence against uptrend, not 'normal cooling' - was called 'normal' in January 2022 before 30-50% drops

→ vs aggressive: Forward P/E of 17.9x is not 'attractive' - fair value closer to $365 at 15x multiple if estimates merely met; bull case requires unlikely combination of beat AND expansion

→ vs aggressive: Price-to-book as 'buyback artifact' still matters - $43.3B net debt becomes real risk in 93% no-cut regime with oil at $95-100 and trade tensions

→ vs aggressive: 3-4% allocation with 395 stop = 0.29-0.39% at risk is 'dangerously naive' - AMGN already dropped after hours on unrelated pelacarsen failure; Tavneos or competitor news could cause 5-8% overnight gap making stops meaningless

→ vs aggressive: Barron's observation that AMGN declined on positive Repatha data 'trumps count of bullish headlines' - positive news not moving stock signals rejection at highs, not 'expectations reset'

→ vs aggressive: Tavneos UK withdrawal as 'localized' is unknown and asymmetric - doesn't help bull case if localized but could meaningfully impact revenue if spreads

→ vs aggressive: Low beta and dividend at 2.27% don't protect from multiple compression - 2022 showed low beta stocks fell 15-25% when rates rose regardless

→ vs aggressive: Healthcare's 23.2% six-month outperformance is 'crowded trade vulnerable to mean reversion' not bullish - marginal buyer exhausted, marginal seller has dry powder

→ vs aggressive: Tiered entry plan (50% on breakout above $454, 50% on pullback, 50% on capitulation) is not HOLD - it's 'fully deployed strategy that triples position size at peak confidence'

HOLD AMGN at 2.5-3% position cap (reduced from 3-4%) with modified tiered entry conditions; favor patience and require momentum confirmation before adding

• Price above 10 EMA, 50 SMA by 10.6%, and 200 SMA by 23.4% confirms intact uptrend
• AMGN has $8.65B trailing FCF, 1.66x dividend coverage, growing cash reserves, declining net debt, 0.43 beta - defensive compounder profile
• Forward P/E of 17.9x with consensus EPS of $24.41 assumes 51% growth - aggressive for company size, multiple compression risk if estimates revised down 10%
• 93% probability of no Fed cuts in 2026; oil threatening $95-$100; macro environment hostile to growth re-rating
• MACD histogram negative; RSI declining from August highs but price still above all three major moving averages
• 10 EMA at $436.60 - barely below spot; post-impulse cooling phase could resolve either direction
• 3-4% position cap limits worst-case damage to ~1-1.5% of portfolio even in $270 scenario
• Tier 1 at $454 requires MACD histogram positive AND price held above breakout for 2 consecutive days
• Tier 2 at $430-$436 is primary add-on zone if RSI holds above 50 with bullish reversal candle
• Tier 3 at $395-$405 only deploys with RSI 35-45, capitulation volume, and stabilization signal (hammer or outside reversal)
• Reduce position cap to 2.5-3% given macro headwinds; rotate freed capital to cash or defensive healthcare ETF
• Consider diversifying healthcare exposure with complementary names (managed care, medical devices) to reduce single-stock concentration

→ vs aggressive: Tier 1 breakout entry at $454 ignores macro risk - buying at 52-week highs with MACD still negative in 93% no-cut environment is fighting the tape; MACD histogram should turn positive before deploying fresh capital

→ vs aggressive: Underestimates multiple compression risk - if consensus EPS of $24.41 is revised down 10%, implied multiple moves from 17.9x to ~20x, making AMGN a premium rather than attractively valued

→ vs aggressive: 'Aggressive capped-risk hold' language erodes discipline and overreaches on execution plan

→ vs aggressive: Wants to keep all exposure in AMGN rather than diversifying healthcare exposure across complementary names

→ vs conservative: Saying HOLD means no entries ever until AMGN proves itself is too rigid - strong trends often make biggest gains after consolidating near highs, and waiting for 20% pullback on low-beta compounder can mean waiting indefinitely

→ vs conservative: $365 fair value scenario (15x multiple) requires both earnings disappointment AND significant multiple compression - two negative events, not most likely base case

→ vs conservative: Overweighting worst-case path - even in 2022-style rate environment, defensive growth names with strong cash flow traded down 15-20%, not to 15x earnings

→ vs conservative: Too dismissive of structural trend support - price still above all three major MAs and 10 EMA at $436.60 is barely below spot; calling it confirmed bearish setup overstates the case

→ vs conservative: Gap risk argument is two-edged - AMGN can gap up on positive regulatory news for Repatha, TEZSPIRE, or MariTide; conservative analysts always emphasize downside gaps while ignoring upside potential that justifies the position